photo of A/Prof David Elliott

A/Prof David Elliott

A/Prof David Elliott

Details

Role Group Leader / Principal Research Fellow
Research area Stem cell biology

Contact

Available for student supervision
Assoc. Prof. David Elliott leads the Heart Disease Group at the Murdoch Childrens Research Institute and he is a principal investigator of the Novo Nordisk Foundation for Stem Cell Medicine (reNEW). David co-directs, with Assoc. Prof. Rachel Conyers, the Australian Cardio-Oncology Registry (ACOR), a national program targeted at improving long-term cardiac health outcomes for childhood cancer survivors. The focus of Assoc. Prof. Elliott’s laboratory is to develop pluripotent stem cell-based models of heart disease and use these models to find new therapies for heart disease. Throughout his career Assoc. Prof. Elliott has made important contributions to understanding the molecular control of heart muscle development, function and disease.

Assoc. Prof. David Elliott completed his PhD on the genetics of heart development at The Victor Chang Cardiac Research Institute and The Walter and Eliza Hall Institute. He continued to post-doctoral studies at the University of Cambridge studying the nervous system in the fruit fly at the Wellcome Trust/Cancer Research UK Gurdon Institute. Assoc. Prof Elliott began using human pluripotent stem cells in a second post-doc with Profs. Andrew Elefanty and Ed Stanley at Monash University where he generated key stem cell lines and identified the first cardiac lineage cell surface markers.
Assoc. Prof. David Elliott leads the Heart Disease Group at the Murdoch Childrens Research Institute and he is a principal investigator of the Novo Nordisk Foundation for Stem Cell Medicine (reNEW). David co-directs, with Assoc. Prof. Rachel Conyers,...
Assoc. Prof. David Elliott leads the Heart Disease Group at the Murdoch Childrens Research Institute and he is a principal investigator of the Novo Nordisk Foundation for Stem Cell Medicine (reNEW). David co-directs, with Assoc. Prof. Rachel Conyers, the Australian Cardio-Oncology Registry (ACOR), a national program targeted at improving long-term cardiac health outcomes for childhood cancer survivors. The focus of Assoc. Prof. Elliott’s laboratory is to develop pluripotent stem cell-based models of heart disease and use these models to find new therapies for heart disease. Throughout his career Assoc. Prof. Elliott has made important contributions to understanding the molecular control of heart muscle development, function and disease.

Assoc. Prof. David Elliott completed his PhD on the genetics of heart development at The Victor Chang Cardiac Research Institute and The Walter and Eliza Hall Institute. He continued to post-doctoral studies at the University of Cambridge studying the nervous system in the fruit fly at the Wellcome Trust/Cancer Research UK Gurdon Institute. Assoc. Prof Elliott began using human pluripotent stem cells in a second post-doc with Profs. Andrew Elefanty and Ed Stanley at Monash University where he generated key stem cell lines and identified the first cardiac lineage cell surface markers.

Top Publications

  • Collier, L, Felmingham, B, Toro, C, Celermajer, D, Mateos, M, Finney, J, Dobson, M, Jadhav, M, La Gerche, A, Horvath, L, et al. Australian Cardio-Oncology Registry: A prospective observational study of patients who have been exposed to cardio-toxic chemotherapy. 2023
    view publication
  • McNamara, JW, Parker, BL, Voges, HK, Mehdiabadi, NR, Bolk, F, Ahmad, F, Chung, JD, Charitakis, N, Molendijk, J, Zech, ATL, et al. Alpha kinase 3 signaling at the M-band maintains sarcomere integrity and proteostasis in striated muscle. Nature Cardiovascular Research 2(2) : 159 -173 2023
    view publication
  • Felmingham, B, Collier, L, Stenta, T, Halman, A, Sadedin, S, Moore, C, Elliott, D, Conyers, R. MARVEL-PIC: minimising adverse drug reactions and verifying economic legitimacy: pharmacogenomic implementation in children. Pathology 55: s6 2023
    view publication
  • Felmingham, B, Collier, L, Stenta, T, Halman, A, Sadedin, S, Moore, C, Elliott, D, Conyers, R. MARVEL-PIC: minimising adverse drug reactions and verifying economic legitimacy: pharmacogenomic implementation in children. Pathology 55: s17 -s18 2023
    view publication
  • Toro, C, Felmingham, B, Jessop, S, Celermajer, DS, Kotecha, RS, Govender, D, Hanna, DMT, O'Connor, M, Manudhane, R, Ayer, J, et al. Cardio-Oncology Recommendations for Pediatric Oncology Patients An Australian and New Zealand Delphi Consensus. JACC Advances 1(5) : 100155 2022
    view publication

Page 1 of 21

Professional activities